Pipeline

Back to overview

AIC649 and IMI CARE approaches

Combatting pandemic viruses such as SARS-CoV-2

We are currently experiencing an ongoing pandemic around the world caused by the beta
coronavirus SARS-CoV-2. As SARS-CoV-2 is a novel human coronavirus, there is no relevant herd
immunity in the population yet, and mutant viruses are appearing at concerning speed. With each
new virus spread, a certain time gap is unavoidable before new vaccines are available. AiCuris is
currently developing an inactivated parapoxvirus, AIC649. In pre-clinical experiments, AIC649
demonstrated anti-viral activity in prophylactic and/or treatment settings against several viruses
(e.g., HBV, HCV, HSV, Influenza, HIV/SIV, SARS-CoV-2). In addition to its primary indication HBV,
AIC649 is thus currently additionally being investigated as a preemptive treatment for SARS-CoV-2
infection, with a pilot trial starting shortly. More importantly, a broad prophylactic use for current
and future viral pandemics of unknown origin will be evaluated.

  Partly funded by the German state of North-Rhine-Westfalia

In addition, AiCuris is a partner in the IMI CARE project, Europe’s largest initiative to accelerate
therapy development for COVID-19 and future coronavirus threats.